Rep. Greg Landsman Sells Bristol-Myers Squibb (NYSE:BMY) Stock

Representative Greg Landsman (D-Ohio) recently sold shares of Bristol-Myers Squibb (NYSE:BMY). In a filing disclosed on April 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bristol-Myers Squibb stock on March 27th. The trade occurred in the Representative’s “ROCKEFELLER CAPITAL MANAGEMENT (2)” account.

Representative Greg Landsman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of CrowdStrike (NASDAQ:CRWD) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of Cadence Design Systems (NASDAQ:CDNS) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Simon Property Group (NYSE:SPG) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of L3Harris Technologies (NYSE:LHX) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Visa (NYSE:V) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Cencora (NYSE:COR) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of Ameriprise Financial (NYSE:AMP) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of Equinix (NASDAQ:EQIX) on 3/27/2025.

Bristol-Myers Squibb Price Performance

BMY traded down $2.75 during trading on Thursday, reaching $50.99. 3,414,580 shares of the stock were exchanged, compared to its average volume of 12,834,116. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a market capitalization of $103.76 billion, a price-to-earnings ratio of -11.59, a P/E/G ratio of 2.07 and a beta of 0.41. The business’s 50 day moving average price is $58.07 and its two-hundred day moving average price is $56.73. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.86%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s payout ratio is currently -56.11%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday, February 7th. Cantor Fitzgerald boosted their price target on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Truist Financial lifted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. The Goldman Sachs Group restated a “neutral” rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday. Finally, Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and lifted their price target for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $57.67.

Insider Activity

In related news, EVP Samit Hirawat purchased 1,823 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was purchased at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the acquisition, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.09% of the company’s stock.

Hedge Funds Weigh In On Bristol-Myers Squibb

A number of large investors have recently modified their holdings of the company. Norges Bank purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $1,989,525,000. Ameriprise Financial Inc. boosted its position in Bristol-Myers Squibb by 59.9% during the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company’s stock worth $1,814,341,000 after purchasing an additional 12,011,983 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in Bristol-Myers Squibb by 701.2% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company’s stock valued at $705,309,000 after purchasing an additional 10,913,708 shares in the last quarter. Wellington Management Group LLP raised its position in Bristol-Myers Squibb by 3,880.0% in the fourth quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company’s stock valued at $338,088,000 after purchasing an additional 5,827,317 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $257,618,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Landsman

Greg Landsman (Democratic Party) is a member of the U.S. House, representing Ohio’s 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Landsman (Democratic Party) is running for re-election to the U.S. House to represent Ohio’s 1st Congressional District. He declared candidacy for the 2026 election.

Greg Landsman was born in Cincinnati, Ohio, and lives in Mt. Washington, Ohio. Landsman earned a B.A. in economics and political science from Ohio University and an M.A. in theological studies, religion, and public policy from Harvard University in 2004. His career experience includes working as the executive director of The Strive Partnership with the KnowledgeWorks Foundation and the director of the Ohio Governor’s Office of Faith-Based and Community Initiatives.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.